JP7293194B2 - 癌治療のための組成物および方法 - Google Patents

癌治療のための組成物および方法 Download PDF

Info

Publication number
JP7293194B2
JP7293194B2 JP2020510543A JP2020510543A JP7293194B2 JP 7293194 B2 JP7293194 B2 JP 7293194B2 JP 2020510543 A JP2020510543 A JP 2020510543A JP 2020510543 A JP2020510543 A JP 2020510543A JP 7293194 B2 JP7293194 B2 JP 7293194B2
Authority
JP
Japan
Prior art keywords
subject
onecut2
day
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020510543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531495A5 (enExample
JP2020531495A (ja
Inventor
フリーマン、マイケル
ロティネン、ミリヤ
ムラリ、ラマチャンドラン
ヨウ、サンギョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of JP2020531495A publication Critical patent/JP2020531495A/ja
Publication of JP2020531495A5 publication Critical patent/JP2020531495A5/ja
Application granted granted Critical
Publication of JP7293194B2 publication Critical patent/JP7293194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
JP2020510543A 2017-08-22 2018-08-22 癌治療のための組成物および方法 Active JP7293194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548879P 2017-08-22 2017-08-22
US62/548,879 2017-08-22
PCT/US2018/047569 WO2019040647A1 (en) 2017-08-22 2018-08-22 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Publications (3)

Publication Number Publication Date
JP2020531495A JP2020531495A (ja) 2020-11-05
JP2020531495A5 JP2020531495A5 (enExample) 2021-10-07
JP7293194B2 true JP7293194B2 (ja) 2023-06-19

Family

ID=65440144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020510543A Active JP7293194B2 (ja) 2017-08-22 2018-08-22 癌治療のための組成物および方法

Country Status (8)

Country Link
US (1) US11529338B2 (enExample)
EP (1) EP3672582A4 (enExample)
JP (1) JP7293194B2 (enExample)
CN (1) CN111182894A (enExample)
AU (1) AU2018321950A1 (enExample)
CA (1) CA3073669A1 (enExample)
IL (1) IL272782A (enExample)
WO (1) WO2019040647A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer
MX2022004145A (es) * 2019-10-07 2022-06-14 De Shaw Res Llc Compuestos heterociclicos de arilmetileno como bloqueadores del canal de potasio tipo shaker kv1.3.
PL447378A1 (pl) * 2023-12-29 2025-06-30 Uniwersytet Medyczny W Lublinie Zastosowanie lepidylin w leczeniu nowotworu układu nerwowego.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166295A1 (en) 2014-04-29 2015-11-05 Ecole Normale Superieure De Lyon Azoaryls as reversibly modulatable tubulin inhibitors
WO2015197909A1 (en) 2014-06-27 2015-12-30 Fermion Oy Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride
JP2017518312A (ja) 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6048877A (en) * 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents
US6218367B1 (en) 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
US20140056807A1 (en) 2012-08-23 2014-02-27 Cedars-Sinai Medical Center Large oncosomes in human tumors and in circulation in patients with cancer
US10188617B2 (en) * 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
WO2014172390A2 (en) 2013-04-15 2014-10-23 Cedars-Sinai Medical Center Methods for detecting cancer metastasis
EP3359692A4 (en) 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD FOR CLASSIFYING AND TREATING CANCER
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166295A1 (en) 2014-04-29 2015-11-05 Ecole Normale Superieure De Lyon Azoaryls as reversibly modulatable tubulin inhibitors
JP2017518312A (ja) 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
WO2015197909A1 (en) 2014-06-27 2015-12-30 Fermion Oy Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride

Also Published As

Publication number Publication date
AU2018321950A1 (en) 2020-03-19
EP3672582A1 (en) 2020-07-01
CN111182894A (zh) 2020-05-19
US11529338B2 (en) 2022-12-20
CA3073669A1 (en) 2019-02-28
EP3672582A4 (en) 2021-05-05
IL272782A (en) 2020-04-30
US20200188373A1 (en) 2020-06-18
JP2020531495A (ja) 2020-11-05
WO2019040647A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US12421185B2 (en) Compositions and methods for treating cancer
RU2701193C2 (ru) Арилхиназолины
US20210015764A1 (en) Methods of reducing inflammation of the digestive system with inhibitors of hif-2- alpha
KR20220133258A (ko) 화합물 및 이의 용도
JP7293194B2 (ja) 癌治療のための組成物および方法
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
US20220257767A1 (en) Ionic liquids for drug delivery
CN104736202B (zh) 用于抑制肌成束蛋白的方法
JP2021176847A (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
IL229988A (en) 4,4,4-trifluoro-n-[(1s)-2[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d] [3]benzazepine-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, its use in the manufacture of medicaments for treating cancer and crystalline hydrates thereof
RU2748696C2 (ru) Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение
US20250034193A1 (en) Phenothiazine derivatives and uses thereof
EP3484474B1 (en) Phenothiazine compounds for the treatment of ribosomal disorders and ribosomopathies
JP2025535017A (ja) Ｉａｐの阻害剤として有用な化合物及び組成物
CN112876463B (zh) 一种制备pd-l1拮抗剂的中间体及其制备方法
CN115724844A (zh) 一种具有抗肿瘤活性的杂环化合物及其用途
KR20150124848A (ko) 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
WO2017223514A9 (en) Lxr inverse agonists for treatment of cancer
CN110105344B (zh) 一种化合物及其合成方法与应用
WO2025221986A1 (en) Targeted camptothecin derivatives for cancer treatment
TW202446378A (zh) 離胺酸乙醯基轉移酶6a(kat6a)抑制劑、其組合及其用途
CN115304598A (zh) 一种杂环类化合物及其制备方法和用途
CN120025325A (zh) 一种并环类化合物、其药物组合物及其应用
CN102816103A (zh) 硫化天冬氨酸修饰的退黑素衍生物及其应用
CN114539204A (zh) 血脑屏障高通透性己糖激酶抑制剂及其合成方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230607

R150 Certificate of patent or registration of utility model

Ref document number: 7293194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150